ENZON ACQUIRES GLOBAL RIGHTS FROM NATIMMUNE FOR ONCOLOGY PRODUCT

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) and the Danish biotech company, NatImmune A/S today announced that they have entered into a license agreement for NatImmune's lead development product, recombinant human Mannan-Binding Lectin (rhMBL), a protein therapeutic being developed for the prevention of severe infections in MBL-deficient individuals undergoing chemotherapy. Under the agreement, Enzon receives exclusive worldwide rights, excluding the Nordic countries, and is responsible for the development, manufacture, and marketing of rhMBL.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1069537XSL_NEWSML_TO_NEWSML_WEB.xml)